ArticleDrug delivery and translational research2022
Rapidly dissolving microneedle patch of amphotericin B for intracorneal fungal infections.
Article in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 67 citations in OpenAlex.
- Advancements and challenges in ophthalmic microneedles to treat eye diseases.Drug delivery · 2026Review
- Dissolving microneedles for inflammatory diseases: Advances in formulation strategies and therapeutic applications.International journal of pharmaceutics: X · 2026Review
- Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma.Ophthalmology science · 2026Article
- Development and Formulation of Nanofiber-Based Ophthalmic Inserts for the Treatment of Fungal Keratitis.Pharmaceutics · 2026Article
- Microneedle technology in the treatment of ocular diseases: Advances and applications.Asian journal of pharmaceutical sciences · 2026Review
- Voriconazole nanosuspension-loaded ocular bilayer dissolving microneedle patch for the management of fungal keratitis.Drug delivery and translational research · 2026Article
- A Dissolving Microneedle Design for Poorly Water-Soluble Drugs for Enhanced Skin Permeation and Transdermal Delivery Fabricated Using 3D Printing.Micromachines · 2026Article
- Microneedle loaded with luteolin-colostrum-derived exosomes: a dropless approach for treatment of glaucoma.Drug delivery and translational research · 2026Article
- Recent Advances in Artificial Intelligence and Nanotechnology-Driven Strategies for Diagnosis and Therapy of Ocular Diseases.Current drug delivery · 2026Review
- A mosquito proboscis-inspired cambered microneedle patch for ophthalmic regional anaesthesia.Journal of advanced research · 2025Article
- Dissolving microneedles fabricated from 3D-printed master molds for application in veterinary medicine.Scientific reports · 2025Article
- Microneedles for controlled and sustained intraocular drug delivery.NPG Asia materials · 2025Review
- Development of Transdermal Drug Delivery Approaches to Combat Diabetes: An Update.Current drug metabolism · 2025Review
- Amphotericin B Ocular Films for Fungal Keratitis and a Novel 3D-Printed Microfluidic Ocular Lens Infection Model.Journal of fungi (Basel, Switzerland) · 2024Article
- Revolutionizing Eye Care: Exploring the Potential of Microneedle Drug Delivery.Pharmaceutics · 2024Review
- Microneedles mediated-dermal delivery of Vitamin C: Formulation, characterization, cytotoxicity, and enhancement of stability.Heliyon · 2024Article
- Article
- Two-Photon and Multiphoton Microscopy in Anterior Segment Diseases of the Eye.International journal of molecular sciences · 2024Review
- Article
- Rapidly dissolving bilayer microneedles enabling minimally invasive and efficient protein delivery to the posterior segment of the eye.Drug delivery and translational research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic fungal infection of the cornea could lead to blindness if not treated properly. Topical amphotericin B (AMP-B) is considered the first treatment of choice for ocular fungal infection. However, factors related to its poor solubility and penetration through intact cornea lead to poor bioavailability. Microneedles (MNs) are emerging as a minimally invasive method to enhance ocular drug delivery. This study aims to investigate the potential use of biodegradable poly(vinylpyrrolidone) (PVP) and hyaluronic acid (HA)-based rapidly dissolving MNs for delivery of AMP-B to treat fungal infection. The data obtained illustrates PVP/HA MN arrays' reproducibility, good mechanical strength, and faster dissolution with 100% drug recovery. Multiphoton microscopic results revealed that MNs successfully penetrate the corneal tissue and enhance AMP-B permeation through corneal layers. Furthermore, PVP/HA MN arrays showed high solubility. Both PVP and HA successfully decreased AMP-B cytotoxicity when compared to free drug. More interestingly, the biocompatible MN formulations preserved the antifungal activity of AMP-B, as demonstrated by significant inhibition of fungal growth. Therefore, this study shows the feasibility of ocular delivery of the poorly soluble AMP-B using a fast-dissolving MN patch.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.